कंपनी का अवलोकन
AnaptysBio, Inc. operates as a clinical-stage biotechnology firm dedicated to developing immunology therapeutics specifically for autoimmune and inflammatory diseases within the United States market. The company functions within the healthcare sector and the biotechnology industry, a classification that signifies its focus on innovative drug discovery and development rather than established consumer products. This entity currently maintains a market capitalization of $1.97B while generating an annual revenue of $234.60M and employing 104 individuals. The combination of a nearly $2 billion valuation with revenue under $250 million suggests the company is a growth-stage enterprise where market expectations are priced heavily on the potential of future product launches rather than current profitability. The significant gap between its market cap and revenue indicates that investors are assigning a high premium to the pipeline's clinical prospects, particularly regarding its flagship asset Rosnilimab which completed a Phase 2b trial.
वित्तीय स्वास्थ्य
The company reported a revenue of $234.60M for the trailing twelve months, yet posted a net income of -$13,232,000, while achieving an EBITDA of $48.45M. The substantial disparity between the positive EBITDA and the negative net income reveals a significant cost structure burden, primarily driven by non-operating expenses or interest costs that erode bottom-line profitability despite strong operational cash generation. Free cash flow stands at $19.34M, which provides the company with essential financial flexibility to fund ongoing research and development programs without relying immediately on external capital markets. Gross margin is reported at 42.0%, indicating that the company retains a healthy portion of revenue after direct production costs, typical for biopharma before accounting for R&D and commercialization overheads. Operating margin reaches an impressive 61.8%, suggesting efficient core operations, whereas the profit margin sits at -5.6%, reflecting the net impact of financing and other comprehensive income statement items. Total cash holdings of $311.64M exceed total debt obligations of $290.64M, creating a net cash position that mitigates liquidity risk, although the debt-to-equity ratio of 781.08 highlights a highly leveraged capital structure relative to shareholders' equity. The current ratio of 9.07 demonstrates robust short-term liquidity, as the company possesses nearly ten times the current assets required to settle its short-term liabilities. Return on equity is -24.5%, indicating that the company is currently diluting shareholder value due to net losses, while return on assets stands at 7.1%, showing that the asset base is generating positive operating returns before financing costs.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is listed as N/A due to the lack of recent earnings, while the forward P/E is -19.37, implying that the market anticipates a return to profitability or is valuing the stock based on anticipated future earnings rather than current performance. The price-to-book ratio of 51.61 indicates a substantial market premium over the company's book value, reflecting high expectations for future clinical successes that are not captured in current asset balances. The price-to-sales ratio is 8.40, and the EV/EBITDA stands at 40.23, both of which are alternative valuation metrics suggesting that the stock is priced significantly higher than traditional multiples, consistent with a clinical-stage asset awaiting regulatory approval. The 52-week high is $69.11 and the 52-week low is $15.40, establishing a wide trading range that reflects high volatility in the biotechnology sector. Without a specific current price provided in the source data to calculate the exact percentage difference, the stock's position relative to this range remains indeterminate based strictly on the available facts, though the wide range itself signals significant price sensitivity. The beta value of 0.41 suggests that the stock exhibits lower price volatility relative to the broader market, moving less than half as much as the overall index in response to market fluctuations.
Growth & Income
Revenue growth year-over-year is reported at 151.1%, demonstrating an aggressive expansion in top-line sales, whereas earnings growth is N/A due to the company's current unprofitable status. The divergence between high revenue growth and the absence of earnings growth implies that the company is prioritizing market capture and clinical progress over immediate profitability, a common strategy in the biotechnology sector. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash is reinvested into research, development, and operational scaling rather than distributed to shareholders. This reinvestment strategy is essential for a clinical-stage firm where capital expenditure is required to advance pipeline assets through regulatory pathways. The overall growth and income profile is characterized by rapid revenue expansion and zero dividend distribution, focusing entirely on long-term value creation through potential future product approvals rather than current income generation.